EUVIMEDEUVIMED entdecken
Delphi-Studie

Optimizing Frontline Targeted Therapies in Chronic Lymphocytic Leukemia: An Italian Inter‐Regional Delphi Consensus on Patient Risk Stratification, Cardiovascular Safety, and Endpoint Interpretation

Stefano Molica iD, Giacomo Loseto, Elsa Pennese iD, Francesco Aji, Angelo Fama, Annamaria Giordano, Giulio Giordano iD, Francesca Immacolata Merchionne, Rosanna Maria Miccolis, Gaetano Palumbo, Pamela Pinto, Sara Plebani und 10 weitere

European Journal of Haematology · 13.11.2026

DOI: 10.1111/ejh.70358 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift European Journal of Haematology, online erschienen am 13.11.2026. Verfasst von Stefano Molica und 21 weiteren Autor:innen. Beteiligte Einrichtung: York-Hull Medical School, Hull, UK. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While landmark trial data have established targeted agents as the frontline standard of care in chronic lymphocytic leukemia (CLL), real‐world clinical gaps remain regarding high‐risk disease biology, patient frailty, cardiovascular comorbidities, healthcare accessibility, and the clinical interpretation of surrogate endpoints.

Methods

A modified two‐round Delphi process engaged an expert panel of 19 Italian hematology specialists and a multidisciplinary scientific board to evaluate 16 evidence‐based statements across four key clinical domains. Statements were formulated based on literature evidence‐informed from a systematic review of the literature. When high‐tier evidence was lacking, statements used lower‐level data and expert consensus to address clinical gaps. Consensus was pre‐defined as an aggregate agreement of 70% using a forced‐choice 4‐point Likert scale.

Results

Continuous monotherapy with second‐generation covalent BTK inhibitors (cBTKis) was preferred over time‐limited regimens for patients with TP53‐disrupted disease (94.6%), individuals aged > 80 years or meeting frailty criteria (100%), and those with socio‐logistic or caregiver constraints (95.0%). Conversely, time‐limited regimens were universally favored for fit patients aged < 70 years without TP53 aberrations (100%), while remaining a viable option in young, fit patients with TP53 disruptions (78.9%). Baseline cardiovascular risk stratification using population‐validated tools (SCORE2, SCORE2‐OP, SCORE2‐Diabetes) reached 85.0% agreement. Second‐generation cBTKis were preferred over ibrutinib in patients with elevated cardiovascular risk (95.0%). Panelists agreed that undetectable measurable residual disease (uMRD) is not a universal surrogate for progression‐free survival (70.0%). Time to next treatment (TTNT) was unanimously endorsed as an efficacy indicator for time‐limited therapy (100%), but viewed primarily as a safety surrogate during continuous cBTKi therapy (79.0%). Upon relapse after time‐limited cBTKi–venetoclax therapy, re‐challenge with a covalent BTKi was established as the preferred option (89.5%).

Conclusion

This consensus bridges clinical guidelines and real‐world practice, providing a structured framework that incorporates molecular risk, functional frailty, cardiovascular scoring, and healthcare accessibility to guide frontline CLL management.

Schlagwörter

Stichwörter der Autor:innen

Delphi consensusTP53 abnormalitycardio‐oncologychronic lymphocytic leukemia (CLL)second‐generation BTK inhibitors (2G BTKi)treatment algorithmvenetoclax

Autor:innen und Institutionen

  • York-Hull Medical School, Hull, UK.
  • UOC Ematologia, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • UOC Ematologia, Presidio Ospedaliero Pescara, Pescara, Italy.
  • UO Ematologia, Ospedale "Cardinale G. Panico", Tricase, Italy.
  • UO Ematologia, Ospedale "Giuseppe Mazzini", Teramo, Italy.
  • UO Ematologia, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy.

ORCID-Profile: Stefano Molica, Elsa Pennese, Giulio Giordano, Antonio Giovanni Solimando, Lorenzo Tonialini, Vincenzo Fraticelli, Daniela D'Angela, Stefano Oliva, Alessandro Maggi

Zitieren

APA

Molica, S., Loseto, G., Pennese, E., Aji, F., Fama, A., Giordano, A., Giordano, G., Merchionne, F. I., Miccolis, R. M., Palumbo, G., Pinto, P., Plebani, S., Scardino, S., Schiattone, L., Solimando, A. G., Specchia, M. R., Tonialini, L., Fraticelli, V., Scalzulli, P. R., …, & Maggi, A. (2026). Optimizing Frontline Targeted Therapies in Chronic Lymphocytic Leukemia: An Italian Inter‐Regional Delphi Consensus on Patient Risk Stratification, Cardiovascular Safety, and Endpoint Interpretation. European Journal of Haematology. https://doi.org/10.1111/ejh.70358

Vancouver

Molica S, Loseto G, Pennese E, Aji F, Fama A, Giordano A, et al. Optimizing Frontline Targeted Therapies in Chronic Lymphocytic Leukemia: An Italian Inter‐Regional Delphi Consensus on Patient Risk Stratification, Cardiovascular Safety, and Endpoint Interpretation. European Journal of Haematology. 2026. doi:10.1111/ejh.70358

BibTeX
@article{Molica2026,
  author = {Molica, Stefano and Loseto, Giacomo and Pennese, Elsa and Aji, Francesco and Fama, Angelo and Giordano, Annamaria and Giordano, Giulio and Merchionne, Francesca Immacolata and Miccolis, Rosanna Maria and Palumbo, Gaetano and Pinto, Pamela and Plebani, Sara and Scardino, Stefania and Schiattone, Luana and Solimando, Antonio Giovanni and Specchia, Maria Rosaria and Tonialini, Lorenzo and Fraticelli, Vincenzo and Scalzulli, Potito Rosario and D'Angela, Daniela and Oliva, Stefano and Maggi, Alessandro},
  title = {Optimizing Frontline Targeted Therapies in Chronic Lymphocytic Leukemia: An Italian Inter‐Regional Delphi Consensus on Patient Risk Stratification, Cardiovascular Safety, and Endpoint Interpretation},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70358}
}
Kostenlos starten →